Background {#Sec1}
==========

Mycetoma continues to pose huge public health threat in many tropical and sub-tropical countries \[[@CR1], [@CR2]\]. If not detected and managed early, it causes gruesome deformity of the limbs, severe disability, premature termination of occupation, difficulty in finding jobs and partner among young adults and accelerates the rate of drop outs from school in children \[[@CR1]\]. Just like leprosy, in which stigma affects many dimensions of victim's life \[[@CR3]\], mycetoma is also plagued by various socio-economic consequences \[[@CR4]\]. Though uncertainty hovers on its actual global incidence, a field survey from West Nile State of Sudan, a country uniquely believed to be the most endemic in the world, yielded a prevalence of 14.5/1000 population in 2010 \[[@CR1], [@CR5]\]. Several autochthonous and imported cases have also been reported from Europe \[[@CR6]--[@CR8]\]. Prolonged diagnostic delays complicate mycetoma as seen in a patient (infected with *Aspergillus nidulans*) from Senegal with a diagnostic delay of 15 years \[[@CR9]\]. Despite its several worrisome impacts, mere mentioning of mycetoma still steers an astonishment. This is probably due to insufficient awareness of its existence as a consequence of low recognition and reporting \[[@CR4]\] as it is not a reportable disease \[[@CR10]\]. This situation may predispose patients to misdiagnosis \[[@CR11]\] and eventual mistreatment \[[@CR12]\] in a scenario where limitation of diagnostic tools prevails, and health personnels are left handicapped with little or no option but to clinically diagnose the patients \[[@CR13]\]. Mycetoma still faces additional challenges such as lack of standardized treatment and strategic public health control guidelines by the World Health Organization (WHO) making its management to be exclusively based on physician's discretion.

Since the clinical outcome of mycetoma is associated with disease severity \[[@CR14]\], it is truism that early commencement of appropriate regimen will reduce disability or disfigurement \[[@CR1]\]. This can be achieved through prompt and accurate identification of mycetoma amidst other diseases mimicking its presentation \[[@CR15]\] and careful distinction of eumycetoma from actinomycetoma \[[@CR13]\]. In this review we seek to give an overview on the clinical presentation of mycetoma in early and late phases which may assist in recognising the disease in its various forms of appearance, to distinguish actinomycetoma from eumycetoma and the two from other differentials so that appropriate management can be initiated or referral to higher facility undertaken timely. Additionally, a suggested algorithm to augment knowledge in making diagnosis in the resource-limited fields is proposed. Diagnostic tools are also highlighted to help guide investigation to make accurate diagnosis in facilities which possess such tools. A suggested control measure which can be used in educating the community thereby reducing their exposure to risk factors during field work has been equally offered.

Distribution of mycetoma {#Sec2}
========================

Geographical areas {#Sec3}
------------------

Mycetoma usually occurs within 15° south to 30° north of the equator \[[@CR1], [@CR2], [@CR16]--[@CR20]\] situated around the tropic of cancer \[[@CR15], [@CR21]--[@CR24]\]. This area includes India, Yemen, Saudi Arabia, Mexico, Venezuela, Argentina, Colombia and Brazil \[[@CR2], [@CR25]--[@CR31]\]. In Africa, cases are seen in Sudan, Nigeria, Mauritania, Ethiopia, Chad, Kenya, Djibouti, Cameroon, Somalia, Tunisia, Niger and Senegal \[[@CR32]--[@CR38]\]. Mycetoma is also reported from Laos, Singapore, Malaysia, Philippines, Indonesia, Cambodia, Thailand and Vietnam \[[@CR17]\]. Occasional reports of mycetoma appears in temperate regions of European countries such as Germany, Albania, Bulgaria, Greece, Italy, and Turkey \[[@CR11], [@CR39]--[@CR46]\]. In France, mycetoma has been reported in migrants from Africa \[[@CR7], [@CR8]\]. Sporadic cases have also been reported from subtropical regions of south-western United States \[[@CR47]\]. In general, mycetoma is believed to have much wider distribution but this is hampered by misdiagnosis and isolation of cases as seen in a case report from south Africa \[[@CR48]\].

Eumycetomas predominantly occur in Africa and Southern Asia with *Madurella mycetomatis* being the most frequent eumycete accounting for 70% of all cases in Sudan \[[@CR22]\]. On the other hand, Actinomycetomas are predominately seen in the Americas with *Nocardia brasiliensis* being the most prevalent organism responsible for 86% of all cases in Mexico \[[@CR21]--[@CR23]\]. A retrospective study in Mexico reported a cumulative of 3933 cases of mycetoma, of which 97% were actinomycetoma while only 3.5% were eumycetoma \[[@CR1]\].

Aetiology and host of mecetoma {#Sec4}
------------------------------

Currently, over 56 taxonomically varying organisms, either of fungal (eumycetoma) or bacterial (actinomycetoma) origin have been implicated as causative agents of mycetoma \[[@CR1]\] (Additional file [1](#MOESM1){ref-type="media"}). Most frequent organisms causing actinomycetoma are *Streptomyces somaliensis*, *Actinomadura madurae*, *A. pelletieri*, *Nocardia brasiliensis* and *N. asteroides*, while the most common pathogens reported in eumycetoma are *M*. *mycetomatis*, M. *grisea*, *Pseudoallescheria boydii and Leptosphaeria senegalensis* \[[@CR49]\].

Mycetoma occurs in all age groups and is most often seen in the age range of 20--40 years \[[@CR1], [@CR2], [@CR50]\] but rarely seen in children. More males than females are affected \[[@CR15]\] and it commonly occurs in field labourers and cultivators whose occupation involves direct contact with the soil \[[@CR16], [@CR50]\]. No known vector or animal reservoir has been established, however mycetoma in animals has been described to be either infected experimentally or naturally \[[@CR1]\]. In humans, mycetoma naturally progresses from early to chronic phase.

Pathogenesis {#Sec5}
============

Though several people are exposed to the causative agents of mycetoma, only few come down with the disease \[[@CR23]\]. An inter play of pathogen, host and environment occurs in the pathogenesis of mycetoma \[[@CR49]\]. Inoculation of the etiologic agents (which usually thrive well in the favorable climatic conditions of the mycetoma belt) occurs when human makes contact with soil, thorn, etc. during manual activities \[[@CR23], [@CR49]\]. Initially a local host response characterized by a nonspecific inflammatory response and neutrophil chemotaxis occur \[[@CR23]\]. This non-specific response subsequently becomes more organized and cellular \[[@CR49]\]. Macrophages and monocytes migrate to the site of infection and their micro-biocidal activities are enhanced by cytokines stimulation (interferon gamma and tumor necrosis factor alpha) \[[@CR23]\]. A study has demonstrated that following stimulation of peripheral blood mononuclear cells by *M. mycetomatis antigen*s, T helper (Th)2-like responses \[interleukin (IL)-10 and IL-4\] are produced in primary lesions, and in draining lymph nodes in *S. somaliensis* infection \[[@CR49]\]. Mahgoub et al. studied the T cell-mediated immune response to eumycetoma fungi with a subsequent claim that eumycetoma patients presented a weak cell-mediated response \[[@CR51]\]. Protective effect of antibodies has been shown to be produced by IgM but not IgG in experimental mice \[[@CR49]\]. The role of genetics has also been studied and found chitotriosidase, an enzyme, to be responsible for the pathogen-eliminating immune response by binding to fungal chitin in mycetoma grain. Thus its polymorphism which results in decreased activity of chitotriosidase enzyme was found to be associated with increased likelihood of developing eumycetoma \[[@CR52]\].

Clinical presentation {#Sec6}
=====================

Characteristic features of eumycetoma and actinomycetoma closely resemble each other and their differentiation is required for proper management. Their characteristics features are shown in Table [1](#Tab1){ref-type="table"} while a concise clinical differentiation between eumycetoma and actinomycetoma is provided in Table [2](#Tab2){ref-type="table"}. Figure [1](#Fig1){ref-type="fig"} shows a normal foot and the foot disfigured by the destructive nature of mycetoma due to delay in instituting clinical management.Table 1Characteristic features of eumycetoma and actinomycetomaCharacteristicsEumycetomaActinomycetomaCausative agentsFungi \[[@CR32]\]Bacteria \[[@CR32]\]GeographyCommon in Africa and India \[[@CR1]\]Common in Latin America \[[@CR1]\]OccupationField workers \[[@CR1]\]Field workers \[[@CR1]\]Age groupCommon in 20--40 years \[[@CR1]\]Common in 20--50 years \[[@CR1]\]Anatomical parts affectedUsually hand, feet and other parts of arms and legs \[[@CR1]\]Usually chest, abdomen and head \[[@CR1]\]Course of progressionSlow \[[@CR64]\]More rapid and inflammatory \[[@CR64]\]Sinus (number, morphology)Few, proliferative, protuberant \[[@CR1]\]Many, depressed, flat \[[@CR1]\]FistulaFew \[[@CR32]\]Many \[[@CR32]\]Bone invasionDelayed \[[@CR32]\]Rapid \[[@CR32]\]Bone cavities on radiographFewer but larger with clear margins \[[@CR32]\]Numerous, small with unclear margins \[[@CR32]\]Lymphatic spreadOccassional \[[@CR1]\]Frequent \[[@CR1]\]Veins proximal to lesionCommonly dilatedSeldom dilatedGrains sizeLarger (0.5--2 mm) \[[@CR64]\]Smaller (20--100 μm) \[[@CR64]\]Grain textureCoarse \[[@CR64]\]Fine \[[@CR64]\]PigmentMelanin \[[@CR64]\]Absent \[[@CR64]\]Hyphae \[[@CR64]\]Septate (4--5 μm thick)Fine, branching filaments (\< 1 μm)Acid fast stainingNegative \[[@CR64]\]Weakly acid fast (e.g. *Nocardia*)Masson--Fontana silver stainingPositive \[[@CR64]\]Negative \[[@CR64]\]PAS stainingPositive \[[@CR64]\]Negative \[[@CR64]\]GMS stainingPositive \[[@CR64]\]Positive \[[@CR64]\]B and B stainingNegative \[[@CR64]\]Gram positive \[[@CR64]\]Ultrasound featuresHyperechogenic \[[@CR1]\]Less echogenic \[[@CR1]\]TreatmentDrugs (antifungal) + surgery \[[@CR1]\]Drugs (antibiotics) \[[@CR1]\]*GMS* Grocotts Methenamine silver Stain, *B and B* Brown and Brenn stain, *PAS* periodic-acid Schiff stainingTable 2Usefulness and pitfalls of diagnostic tools used in mycetomaDiagnostic methodsUsefulnessPitfallsClinicalUtilised in endemic areas where diagnostic facilities are lacking\
It boosts referralDoes not identify the etiologic agent\
Does not reveal the spread of disease along the different tissue planes and boneImaging X-rayCan determine the extent of lesions\
Multiple features can be detected\
Help plan treatment strategy\
Can be used in low-resource settings once expertise is availableRequires expert for interpretation UltrasoundDetermine the extent of lesions\
Differentiate between mycetoma and non-mycetoma lesions\
Differentiate between eumycetoma and actinomycetoma\
Help plan appropriate treatment strategy\
Can be used in low-resource settings once expertise is availableCannot differentiate between different causative agents\
Not readily available in the field or peripheral hospitals\
Requires expert for interpretation MRIDetermine the extent of lesions\
Fast and non-invasive\
Help plan treatment strategyUnsuitable for discrimination\
Available only in tertiary facilities\
Requires highly expert persons CTDetermine the extent of lesions\
Discriminate eumycetoma between actinomycetoma\
It is fast and non-invasive\
Help plan appropriate treatment strategyNot specific for early bony involvement\
Available only in tertiary facilities\
Requires highly expert personsLaboratory MicroscopyCheaper and easy to use\
Can be utilised in the field and resource constraint settings\
Gram stain can distinguish fungal from bacteria agents\
Lacto-phenol cotton blue stain can differentiate fungal from bacterial filaments\
Acid fast stain helps identify the positive hyphae of *Nocardia*Cannot identify specific etiologic agents CultureGold standard for aetiology identification\
Aids in proper management of patientsTime consuming, contamination is common, high expertise needed\
Mostly available only in tertiary health care facilities Histology/FNACSimple, rapid, sensitive and invasive but well tolerated by most patients\
Can distinguish eumycetoma from actinomycetomaRequires expert to perform the procedure\
A pathologist is required to interpret the results\
General or regional anaesthesia needed\
Biopsy procedure requires experts SerologyLess invasive procedure\
Cheaper and less time consumed\
Useful for measuring therapeutic responseCannot reliably diagnose mycetomca\
Pure antigens needed\
Cross reactivity is a common challenge Molecular-PCRFast, reliable and easy identification of causative agents\
Important for studying epidemiology of mycetoma agents\
Useful for generating accurate therapeutic dataExpensive, not readily available in endemic areas\
Only available in tertiary facilities\
Inappropriate for use in the field Molecular-LAMPReliable identification of causative agents\
Can be used in resource-limited settings\
Relatively cheaper and easier compared to PCR\
User friendlyLess specific than PCR in identifying etiologic agents, possibility of field application*MRI* magnetic resonance imaging, *CT* computed tomography, *PCR* polymerase chain reaction, *FNAC* fine needle aspiration cytology, *LAMP* loop-mediated isothermal amplificationFig. 1Schematic diagram showing: **a** a normal foot and **b** foot disfigured by the destructive nature of mycetoma due to delay in instituting clinical management. Figures are schematic presentation and may not scale to actual measurements

Early phase of mycetoma {#Sec7}
-----------------------

At early onset of the disease, a papule, a nodule, an abscess or just an induration lacking a clear margin can be seen. At this point, a meticulous history may reveal an episode of trauma or walking barefooted prior to presentation of symptom or sign. More often, this could be difficult to elicit since patients fail to notice such trivial events \[[@CR47]\]. Though the precise incubation period of mycetoma is still unknown, the interval between initial infection to presentation in the health facility may vary from 3 months to 50 years \[[@CR1]\]. The epidermis may become hypo- or hyper-pigmented and the nodules which increase in size eventually rupture along fascial plains to form secondary nodules \[[@CR14]\]. These ruptured nodules continue as a sinus tract discharging fluid which contains grains, and is usually characterised by alternating episodes of healing and breakdown as the affected area progressively enlarges, becomes more oedematous, nodulated and deformed \[[@CR47]\]. Pain is hardly felt at this stage and has only been reported in 15% of patients \[[@CR8]\]. This absence of pain has been attributed to production of anaesthetic substances and only in rare cases, pain can results from super-imposed bacterial infection, bone expansion or nerve damage in the later part of the disease course \[[@CR8]\].

Late phase of mycetoma {#Sec8}
----------------------

Mycetoma patients usually present late with the classical characteristic triad of a painless subcutaneous mass, multiple sinus, and discharge containing grains \[[@CR53]\]. This delay in presentation of patients to health centres in chronically deformed state is attributed to the painless, slowly progressive nature of the disease coupled with poor health education and low socio-economic status \[[@CR54]\]. Vital structures such as tendons and nerves are usually well preserved until late in the disease course due to adequate supply of blood in mycetoma \[[@CR2], [@CR20]\]. Regional lymph nodes may enlarge as a result of superimposed bacterial infection or immune complex deposition \[[@CR20]\]. Infection is usually confined except in patients with immuno-suppression or septicaemia \[[@CR2]\]. Although diverse aetiological agents are implicated in mycetoma, the clinical presentations usually mimic one another, and apparently most cases may appear similar \[[@CR1]\]. In spite of shared similarity, actinomycetoma tends to be more aggressive and destructive, rapidly proliferating, inflammatory and it invades bone faster than eumycetoma \[[@CR14]\].

Anatomical preference {#Sec9}
---------------------

As expected, mycetoma develops on body part which frequently comes into contact with the habitat of these saprophytic organisms. Foot is the most predominantly affected part of the body (82% of cases), followed by hand (7%) \[[@CR20]\]. In cases where the foot is involved, the dorsum is frequently affected \[[@CR2]\]. Other parts such as the knee, arm, leg, head, neck, thigh, perineum, chest, abdominal walls, facial bones, mandible, paranasal sinuses, eyelid, vulva, orbit, and scrotum are seldom affected \[[@CR2]\]. Cysts may develop in situations where the elbow, knee and buttocks are involved \[[@CR50]\]. In regions such as Mexico where labourers carry woods and other agricultural materials on their back, mycetoma commonly affects this area with subsequent complication of paraplegia due to direct spread to the vertebral bone and spinal cord \[[@CR1]\]. Cases of mycetoma affecting the scalp \[[@CR55]--[@CR57]\] and cerebrum have also been documented \[[@CR58]--[@CR61]\].

Mycetoma in pregnancy {#Sec10}
---------------------

The preponderance of mycetoma in male relative to female is a usual finding \[[@CR15]\]. This discrepancy has stirred curiosity among researchers to unveil the factors responsible for this marked difference which has been explained as the physiological effects of progesterone levels in female that may have inhibitory effects on the proliferation of some causative agents \[[@CR16]\]. Interestingly, contradictory to this thought, other researchers found mycetoma to be more active and aggressive during pregnancy \[[@CR62], [@CR63]\]. This aggression of mycetoma in gestation has been found to be associated with alteration in hormonal environment and suppressed immune response during pregnancy \[[@CR2]\]. While some suggests hormonal effects, others attributed this sex variation to greater exposure (physical) of men than women to agricultural activities \[[@CR1]\]. However, in some endemic regions, female are more committed to field work than men yet mycetoma is more prevalent in men supporting the idea of possible hormonal effect \[[@CR2]\]. Therefore, the actual reasons behind this difference is still controversial.

Mycetoma in children {#Sec11}
--------------------

Generally, mycetoma is thought to occur infrequently in children (reported incidence, 3.0--4.5%) and probably the youngest reported case was a 2-year-old boy from India \[[@CR64]\]. Even though the clinical features, radiological, cytological and ultrasonography findings in children are not different from those seen in adults, the rate of amputations in children are however, lower which can be attributed to shorter duration of disease and early phase reporting to the health facility. In cases of amputation, children, however, are relatively more liable to become social outcasts, and are thus at increased risk of dropping out of school \[[@CR1]\].

Diagnosis {#Sec12}
=========

A comprehensive summary on features of mycetoma is described and an algorithm which may guide a physician in approaching a suspected case of mycetoma is suggested (Fig. [2](#Fig2){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}). Patients presenting with papule, nodule, induration, swelling or disfigured foot from endemic region need to be carefully scrutinised, and their age, sex and occupation ought to be kept in mind regarding its occurrence \[[@CR65]\]. These patients rarely complain of pain unlike in elephantiasis where episodic acute painful attacks are experienced \[[@CR66]\]. Yaws mimics mycetoma but due to its contagious nature, close contacts are likely to contract the disease easily and usually occur in childhood with 70% below the age 15 years \[[@CR67]\]. Unlike mycetoma, the lesions are also painful and itchy in Yaws \[[@CR67]\]. Where disease progression is rapid, accompanied by severe weight loss and systemic involvement, malignancy needs to be ruled out \[[@CR68]\]. Chronic bacterial osteomyelitis may mimic it, but it is usually accompanied by fever and pain over affected sites unlike mycetoma except when superimposed by bacterial infection \[[@CR69], [@CR70]\]. Fungal diseases such as botryomycosis, sporotrichosis, blastomycosis, chromoblastomycosis, coccidioidomycosis, phaeohyphomycosis, lobomycosis and paracoccidioidomycosis have close resemblance to mycetoma \[[@CR71]\]. Knowledge of their epidemiology and clinical progression will assist the physician in making a presumptive diagnosis. Focused investigation at various levels of facility also helps the physician to hit the diagnosis as shown in the algorithm (Fig. [2](#Fig2){ref-type="fig"}). Table [1](#Tab2){ref-type="table"} reveals findings and results in some of the available tests to confirm mycetoma and Table [3](#Tab3){ref-type="table"} summarizes the differences between actinomycetoma and eumycetoma. A disease condition producing chronically swollen and deformed foot characterised by draining sinuses should be considered as a differential diagnosis of mycetoma as shown in Table [4](#Tab4){ref-type="table"}. Additionally, some important diagnostic tools, their pitfalls and the level of health care system to find them are provided in Tables [2](#Tab2){ref-type="table"} and [5](#Tab5){ref-type="table"} to aid in diagnosis.Fig. 2Diagnostic algorithm for mycetomaTable 3Major clinical differences between eumycetoma and actinomycetoma: summary of key findingsCharacteristicsEumycetomaActinomycetomaAffected body parts \[[@CR1]\]Usually hand, feet and other parts of arms and legsUsually chest, abdomen and headLesion \[[@CR32]\]Well encapsulated with a clear marginDiffuse, no clear marginDisease progression \[[@CR64]\]SlowMore rapid and inflammatorySinus morphology \[[@CR1]\]Proliferative, protuberantDepressed, flatSinuses \[[@CR32]\]FewManyBone invasion \[[@CR32]\]DelayedRapidBone radiograph \[[@CR32]\]Fewer but larger cavities with clear marginsNumerous, small cavities with unclear marginsColor and texture of grainsDifferent colors, but mostly white or black; coarse textureDifferent colors but not black; fine textureLymphatic spread \[[@CR1]\]OccassionalFrequentDrugs (e.g.) \[[@CR49]\]Antifungals (ketoconazole, voriconazole, posaconazole, etc.)Antibiotics (sulfamethoxazole--trimethoprim, rifampicin, amikacin, etc.)Recurrence \[[@CR1]\]MoreLess Table 4Infectious and non-infectious diseases mimicking mycetoma: consideration for differential diagnosisInfectious diseasesNon-infectious diseasesParasiticTumours Elephantiasis Acral melanomaBacterial Bone cyst Actinomycosis Fibro lipomas Chronic bacterial osteomyelitis Fibroma Syphilis Foreign body granuloma Tuberculosis Ganglion cyst Yaws Giant cell tumourFungal Gouty typhus Blastomycosis Kaposi's sarcoma Botryomycosis Lipomas Chromoblastomycosis Malignant melanoma Coccidioidomycosis Nerve sheath tumours Lobomycosis Osteosarcoma Paracoccidioidomycosis Rhabdomyosarcoma Phaeohyphomycosis Sarcomas (others) Sporotrichosis Subdermal abscessOccupational PodoconiosisDisease names are given in alphabetical order Table 5Level of health care facilities and possible diagnostic approach for mycetomaFacilityMethod of diagnosisFieldClinicalPeripheralClinical, microscopy, radiology (X-ray)DistrictClinical, microscopy, radiology (X-ray, ultrasound)Tertiary and referral centresClinical, microscopy, radiology (X-ray, ultrasound, MRI, CT), culture, histology, serology, molecular (PCR, LAMP)*MRI* magnetic resonance imaging, *CT* computed tomography, *PCR* polymerase chain reaction, *LAMP* loop-mediated isothermal amplification

Treatment {#Sec13}
=========

Treatment of mycetoma is still based on expert opinion in the absence of WHO treatment guideline.

Varying antimicrobial treatment options for actinomycetoma exist. Eumycetoma treatment usually poses a challenge. Antifungals are used, and in many cases, combination of surgery and antifungals are preferred \[[@CR23]\]. Other treatment regimens and their outcomes are also shown in Additional file [1](#MOESM1){ref-type="media"}: Table S2.

Actinomycetoma {#Sec14}
==============

Weilsh, modified Weilsh, two step regimens and other treatment modalities are available. In Weilsh regimen, 15 mg/kg IM of Amikacin in two divided doses + sulfamethoxazole (35 mg/kg/day) and trimethoprim (7 mg/kg/day) in three divided doses for 21 days at 1--3 cycles of 15-days intervals is used in the intensive phase. In its maintenance phase, trimethoprim and sulfamethoxazole (7 and 35 mg/kg/day, respectively) are administered for 2 weeks after the last cycle \[[@CR18]\]. In modified Welsh, 15 mg/kg/day of Amikacin in divided doses + sulfamethoxazole--trimethoprim tablets (35 + 7 mg/kg/day) + rifampicin capsule (10 mg/kg/day) for 21 days at 1--3 cycles of 15 days intervals in the intensive phase is followed by sulfamethoxazole--trimethoprim tablets (35 + 7 mg/kg/day) + rifampicin capsule (10 mg/kg/day) for 3 months in the maintenance phase \[[@CR49]\]. In two step modified regimen, Gentamicin (80 mg twice daily, IV), and cotrimoxazole (two tablets of 960 mg twice daily) for 4 weeks in the intensive phase is followed by Doxycycline (100 mg orally, twice daily) and cotrimoxazole (two tablets of 960 mg twice daily) which are given until 5--6 months after complete healing of all sinuses \[[@CR49]\].

Eumycetoma {#Sec15}
==========

Over 50% of cases treated with imidazoles and triazoles respond well to therapy, especially immunocompetent patients having infections limited to the subcutaneous tissues \[[@CR23]\].

Treatment modalities include itraconazole (200--400 mg/day), ketoconazole (400 mg/day), voriconazole 400--600 mg/day, posaconazole (200 mg, four times daily), terbinafine (500--1000 mg/day), and amphotericin B (0.5--1.25 mg/kg/day) alone or with any combination(s) \[[@CR49]\].

Recommendation on treatment {#Sec16}
===========================

Treatment of both eumycetoma and actinomycetoma is currently based on expert opinion. We encourage active research to establish treatment guideline for it.

Prevention and control {#Sec17}
======================

Since there are no outlined prevention or control programs for mycetoma by WHO till date, we recommend aggressive formal and informal health education, and sensitization in endemic areas for community members regarding protection of exposed parts of the body (by using rubber boots and gloves) during work that are in contact with the habitat of offending organisms (Fig. [3](#Fig3){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}). Early recognition and reporting of suspected cases will reduce severity of complication and improve treatment outcome.Fig. 3Recommended prevention and control strategies for mycetoma(Source of photograph of mycetoma affected leg: <http://www.who.int/neglected_diseases/diseases/massive_foot_mycetoma.jpg>)

Conclusion {#Sec18}
==========

The late presentation of mycetoma patients results to gruesome complication. Early presentation, recognition, reporting and initiation of appropriate regimen is needful in reducing this disability. The clinical overview of mycetoma and the suggested algorithm may assist health workers to suspect and recognise mycetoma amidst other differentials in their community. Since no standard outlined treatment measure has been given by WHO, we have suggested covering of exposed parts of the body during working on the field as a preventive measure to avert contact with infective agents. The suggested preventive and control measures can be utilized by health workers/community leaders to educate people at risk to reduce their risk of exposure and also to report cases early. We recommend that Dermatological diseases with severe physical disability and social stigma leading to isolation like mycetoma needs to be given more attention in research and funding.

Additional file
===============

 {#Sec19}

**Additional file 1.** Information on the causative agents of mycetoma (eumycetoma and actinomycetoma), and their current treatment algorithms.
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